A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-11

Study Completion Date

2024-09-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized phase II study evaluating maintenance therapy after first line induction chemotherapy in metastatic cancer pancreas.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer

NCT02048384

Metastatic Pancreatic Adenocarcinoma

COMPLETED PHASE1

Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer

NCT03959150

Pancreatic Cancer

UNKNOWN PHASE2/PHASE3

Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer

NCT01167738

Pancreatic Cancer

TERMINATED PHASE2

Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma

NCT03633734

Pancreatic Adenocarcinoma Metastatic Chemotherapy Effect

UNKNOWN PHASE1/PHASE2

Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT00209677

Pancreatic Cancer

SUSPENDED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, we aim to evaluate the role of maintenance capecitabine by comparing 2 arms of metastatic cancer pancreas patients in the first line , the first arm will receive 4 months of induction FOLFRINOX the maintenance capecitabine and the second arm will receive 4 months of FOLFRINOX then kept under follow-up:

•Primary end point: PFS.

•Secondary end points: OS, QOL and Toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of Pancreas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

the maintenance arm

in this arm patients will receive 4 months of induction FOLFRINOX then maintenance capecitabine

Group Type EXPERIMENTAL

Capecitabine

Intervention Type DRUG

maintenance capecitabine after 4 months of FOLFRINOX

the control arm

in this arm patients will receive 4 months of FOLFRINOX then kept under follow-up

Group Type OTHER

follow up

Intervention Type OTHER

follow up after 4 months of FOLFRINOX

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Capecitabine

maintenance capecitabine after 4 months of FOLFRINOX

Intervention Type DRUG

follow up

follow up after 4 months of FOLFRINOX

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xeloda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed invasive adenocarcinoma of pancreas.
* Stage 4 disease according to The American Joint Committee on Cancer (AJCC the 8th Edition) 2017.
* Measurable metastases according to RECIST 1.1.
* Patients underwent surgical resection and postoperative evaluation revealed distant metastasis.
* Patients with age ranging from 18 to 69.
* WHO performance status 0-1.
* An adequate bone marrow reserve and adequate liver and renal function as follow: Neutrophils ≥ 1500 cell/dl, Platelets ≥ 100,000 cell/dl, Hemoglobin ≥ 9.0 g/dl, Total bilirubin \< 1.5 × upper normal level (UNL), SGOT and SGPT \< 3 × UNL, Creatinine \< 1.5 × UNL or estimated GFR \> 30 ml/min.
* Adjuvant and neoadjuvant chemotherapies will be permitted if administered more than 6 months before inclusion.
* Patients with biliary or gastroduodenal obstruction must have drainage or surgical bypass prior to starting chemotherapy.
* All patients must have signed and dated informed consent form.

Exclusion Criteria

* Endocrine or acinar pancreatic carcinoma.
* Patients who progressed during FOLFRINOX regimen.
* Pregnancy or breast feeding.
* Patients with complicated systemic diseases such as diabetes, HTN or decompensated liver disease.
* Patients with any serious uncontrolled medical conditions that might compromise study participation: Central nervous system disorders, gastrointestinal tract disorders that interfere with oral medication.
* Patients with history of previous other carcinoma except basal cell carcinoma of the skin, insitu cervical carcinoma or non-metastatic prostate cancer.
* More than grade 1 peripheral neuropathy.
* Brain metastasis.

Minimum Eligible Age

18 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes